Phase I Trial of NPI-0052 Begins

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

SAN DIEGO, Calif—Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

Articles in this issue
Triple-Negative Cancers More Common in Young Black Pts
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'
Study to Examine Outcomes Disparities in Pediatric ALL
Thalidomide Has 'Changed the Paradigm' in Myeloma Rx
CA4P Gets Orphan Drug Status
Testicular Ca Survivors at Increased Risk for CV Events
A Novel Brings a Cancer Research Laboratory to Life
NCCN Reveals New Venous Thromboembolism Guideline
Lapatinib New Option for Metastatic HER2+ Breast Ca
FDA Approves Dacogen for Treating All MDS Subtypes
Noninvasive Ablation Relieves Chronic Chest Wall Pain
GVAX Receives Fast-Track Status
Medicare CAP Vendor Selected
Selective IGF-1R Inhibitor Blocks Colon Cancer Growth
US Cancer Mortality Drops
Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Clinical Implications Remain After Dasatinib CRL in CML/ALL

Clinical Implications Remain After Dasatinib CRL in CML/ALL

Ariana Pelosci
October 28th 2025
Article

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.